MGK_2, OHM, Respert, Sean & so many others, here &
Post# of 153820
(Total Views: 995)
Posted On: 04/01/2024 1:07:46 AM
MGK_2, OHM, Respert, Sean & so many others, here & other sites who's names of course i'm forgetting ---- thank you for the time n efforts.
Been around for a while & remember the days of excitement & expecting being a part of seeing a drug, make a meaningful difference on lives.
Had a little stumble & i call it that for a reason:
1. Although a CEO was doing a stock selling, cash grab of $15m on misleading information, & a couple other conspirator issues, none of them were doing it based on the verge of proving what Dr. J has now called it ---- Laronlimab's true potential. I have fallen back & laughed @ the irony of how bad they've all screwed themselves, for so little temporary "gain", aka: ill-gotten gains.
2. Not only was this company not to survive, unlike i think any have ever seen, but OHM's list of indicies @ 90 or so, mixed with everyone who has shared outstanding medical knowledge & workings, topped with all around patent protections, i can honestly say the realization of what the true potential is, is overwhelmingly shocking.
Im honestly trying to stay level headed & not mentally create success before it's proven. But dam. Wow.
I read a post on a forum, poster mentioned possibly down the road, clinical trials may not even be necessary.
Again, now taking it all in --- LL's known performance to date, lack of warnings, OHM's list, MGK_2's Platform Drug post, inflammation postings, unlimited other helpful posters, i think that poster will also be proven correct.
One, if not the major reason why:
The FDA knows everything @ Cytodyn.
Develop intentions, patents, etc..
On that, im going to throw a little twist using the Feb. 2023 patent.
That patent covers MAB's into of course, OHM's list.
It was said yrs ago FDA didn't yet really understand MAB's. So now, with the patent & all the other sourced reasearch validating Cytodyn's LL vision, FDA not fairly assisting Cytodyn, means no patent liscensing from Cytodyn??
So did the 2023 patent play a big role in all this?
Im just blabbling & adding that for a big who knows, maybe angle, because in the least, it's power can't be overstated. So again, who knows.
All we know is we're getting the fair shot @ just letting the molecule LL, do what it does & start marching towards that status of Platform Drug.
I knew the workings of this company inside & out, but what you guys & Cytodyn have been bringing into picture, is an absolute multiples of past potential brain buster.
Knowledge can be a double edged sword --- the excitement it causes becomes a battle to focus!
LOL!
Although they expected it was close in hand, imagine the feelings running through the Cytodyn team, day FDA lifted the hold.
3 yrs ago Dr. J said:
We don't know yet if Leronlimab is a single...double...triple...or HR
https://youtu.be/lw7jnA0sQRM?si=87PWKaXhVJbJV6dA
Now him & Leronlimab are up to bat.
My bet ---- 2 future HOF inductees.
: )
Been around for a while & remember the days of excitement & expecting being a part of seeing a drug, make a meaningful difference on lives.
Had a little stumble & i call it that for a reason:
1. Although a CEO was doing a stock selling, cash grab of $15m on misleading information, & a couple other conspirator issues, none of them were doing it based on the verge of proving what Dr. J has now called it ---- Laronlimab's true potential. I have fallen back & laughed @ the irony of how bad they've all screwed themselves, for so little temporary "gain", aka: ill-gotten gains.
2. Not only was this company not to survive, unlike i think any have ever seen, but OHM's list of indicies @ 90 or so, mixed with everyone who has shared outstanding medical knowledge & workings, topped with all around patent protections, i can honestly say the realization of what the true potential is, is overwhelmingly shocking.
Im honestly trying to stay level headed & not mentally create success before it's proven. But dam. Wow.
I read a post on a forum, poster mentioned possibly down the road, clinical trials may not even be necessary.
Again, now taking it all in --- LL's known performance to date, lack of warnings, OHM's list, MGK_2's Platform Drug post, inflammation postings, unlimited other helpful posters, i think that poster will also be proven correct.
One, if not the major reason why:
The FDA knows everything @ Cytodyn.
Develop intentions, patents, etc..
On that, im going to throw a little twist using the Feb. 2023 patent.
That patent covers MAB's into of course, OHM's list.
It was said yrs ago FDA didn't yet really understand MAB's. So now, with the patent & all the other sourced reasearch validating Cytodyn's LL vision, FDA not fairly assisting Cytodyn, means no patent liscensing from Cytodyn??
So did the 2023 patent play a big role in all this?
Im just blabbling & adding that for a big who knows, maybe angle, because in the least, it's power can't be overstated. So again, who knows.
All we know is we're getting the fair shot @ just letting the molecule LL, do what it does & start marching towards that status of Platform Drug.
I knew the workings of this company inside & out, but what you guys & Cytodyn have been bringing into picture, is an absolute multiples of past potential brain buster.
Knowledge can be a double edged sword --- the excitement it causes becomes a battle to focus!
LOL!
Although they expected it was close in hand, imagine the feelings running through the Cytodyn team, day FDA lifted the hold.
3 yrs ago Dr. J said:
We don't know yet if Leronlimab is a single...double...triple...or HR
https://youtu.be/lw7jnA0sQRM?si=87PWKaXhVJbJV6dA
Now him & Leronlimab are up to bat.
My bet ---- 2 future HOF inductees.
: )
(15)
(0)